Cancer vaccines: Building a bridge over troubled waters

[1]  Charles H. Yoon,et al.  Landscape of helper and regulatory antitumour CD4+ T cells in melanoma , 2022, Nature.

[2]  M. Clatworthy,et al.  In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue , 2022, The Journal of experimental medicine.

[3]  Guo-Qing Wu,et al.  Immunotherapy of Cancer by Targeting Regulatory T cells. , 2022, International immunopharmacology.

[4]  Zhichen Sun,et al.  Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity , 2022, The Journal of clinical investigation.

[5]  K. Jensen,et al.  Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity , 2022, The Journal of Immunology.

[6]  J. Serody,et al.  B Cell Function in the Tumor Microenvironment , 2022, Annual Review of Immunology.

[7]  T. Schumacher,et al.  Tertiary lymphoid structures in cancer , 2022, Science.

[8]  F. Balkwill,et al.  Harnessing cytokines and chemokines for cancer therapy , 2022, Nature Reviews Clinical Oncology.

[9]  A. Tsung,et al.  Surgery-Mediated Tumor-Promoting Effects on the Immune Microenvironment. , 2022, Seminars in cancer biology.

[10]  Q. Mi,et al.  Plasmacytoid Dendritic Cells and Cancer Immunotherapy , 2022, Cells.

[11]  Xueda Hu,et al.  Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer , 2021, Nature Cancer.

[12]  T. Wróbel,et al.  Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases , 2021, International journal of molecular sciences.

[13]  J. Pelletier,et al.  Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice , 2021, Cell reports. Medicine.

[14]  C. Garbe,et al.  Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy , 2021, Journal for ImmunoTherapy of Cancer.

[15]  A. Richmond,et al.  Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy , 2021, Cancers.

[16]  D. von Laer,et al.  Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect , 2021, Cancers.

[17]  M. Subklewe,et al.  Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens , 2021, Cancer Immunology, Immunotherapy.

[18]  J. Cumming,et al.  STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors , 2021, Molecular Cancer Therapeutics.

[19]  Z. Szallasi,et al.  Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma , 2021, The Journal of clinical investigation.

[20]  D. Czerwinski,et al.  In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity , 2021, Blood.

[21]  G. Coukos,et al.  Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope , 2021, Nature Communications.

[22]  A. Bhutkar,et al.  Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. , 2021, Immunity.

[23]  S. Frigerio,et al.  Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect , 2021, International Journal of Molecular Sciences.

[24]  N. Hacohen,et al.  Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer , 2021, Nature Biotechnology.

[25]  Mohammed Muzamil Khan,et al.  Advances in spatial transcriptomic data analysis , 2021, Genome research.

[26]  G. Nabel,et al.  Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models , 2021, Science Translational Medicine.

[27]  T. Schumacher,et al.  The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues , 2021, Nature Reviews Immunology.

[28]  M. Jager,et al.  Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models , 2021, Pharmaceutics.

[29]  Xiaotang Yang,et al.  Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review , 2021, Frontiers in Oncology.

[30]  S. Riddell,et al.  A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells , 2021, The Journal of clinical investigation.

[31]  J. Aster,et al.  FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity , 2021, Nature Communications.

[32]  A. Letai,et al.  Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer , 2021, Breast cancer research : BCR.

[33]  Todd M. Allen,et al.  Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans , 2021, Nature Immunology.

[34]  David R. Jones,et al.  Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers , 2021, Nature.

[35]  Shuqiang Li,et al.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma , 2021, Nature.

[36]  E. Wherry,et al.  Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation , 2021, Nature Immunology.

[37]  M. Fuentes,et al.  Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies , 2021, Cancers.

[38]  Yulei N. Wang,et al.  Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment , 2021, Immunological reviews.

[39]  A. Vilgelm,et al.  Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer , 2021, Frontiers in Immunology.

[40]  M. Merad,et al.  MDSC: Markers, development, states, and unaddressed complexity. , 2021, Immunity.

[41]  D. Gandara,et al.  ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy , 2021, JCO precision oncology.

[42]  A. Mehta,et al.  Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer , 2021, Frontiers in Immunology.

[43]  Luke H. Hoeppner,et al.  A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. , 2021, Molecular cell.

[44]  A. Murphy,et al.  Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.

[45]  H. Phee,et al.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy , 2021, Frontiers in Immunology.

[46]  D. Irvine,et al.  Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells , 2021, Science Immunology.

[47]  G. Lizée,et al.  Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. , 2021, Cancer discovery.

[48]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[49]  P. Ferrucci,et al.  Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma , 2021, Cancers.

[50]  R. Brekken,et al.  Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer , 2021, bioRxiv.

[51]  Chandler D. Gatenbee,et al.  IgA transcytosis and antigen recognition govern ovarian cancer immunity , 2021, Nature.

[52]  P. Allavena,et al.  Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective , 2021, Clinical Cancer Research.

[53]  G. Coukos,et al.  Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer , 2021, Science Advances.

[54]  K. Shannon,et al.  Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma , 2021, Nature Medicine.

[55]  James J Foti,et al.  An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. , 2021, Cancer discovery.

[56]  Rebecca L. Holden,et al.  Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma , 2021, Nature Medicine.

[57]  A. Regev,et al.  Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors , 2021, Cell.

[58]  J. Herndon,et al.  A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope , 2021, NPJ vaccines.

[59]  T. Kupper,et al.  Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge , 2021, npj Vaccines.

[60]  Nikhil S. Joshi,et al.  Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses , 2021, Cell.

[61]  P. Ascierto,et al.  Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) , 2019, Nature Medicine.

[62]  M. Philip,et al.  CD8+ T cell differentiation and dysfunction in cancer , 2016, Nature Reviews Immunology.

[63]  Nir Hacohen,et al.  Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved , 2020, Cancer Immunology Research.

[64]  A. Shalek,et al.  Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity , 2020, Cell reports.

[65]  P. Danaher,et al.  Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets , 2020, Nature Cancer.

[66]  Ying S. Ting,et al.  A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer , 2020, Cell.

[67]  S. Spranger,et al.  Impact of anatomic site on antigen-presenting cells in cancer , 2020, Journal for ImmunoTherapy of Cancer.

[68]  F. Ginhoux,et al.  Intravenous Nanoparticle Vaccination Generates Stem-Like TCF1+ Neoantigen-Specific CD8+ T Cells , 2020, Nature immunology.

[69]  Z. Szallasi,et al.  Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage , 2020, Science.

[70]  Gregory F. Wu,et al.  cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity , 2020, Nature.

[71]  D. Irvine,et al.  Controlling timing and location in vaccines , 2020, Advanced Drug Delivery Reviews.

[72]  Loise M. Francisco,et al.  The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. , 2020, Cell reports.

[73]  Morten Nielsen,et al.  NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data , 2020, Nucleic Acids Res..

[74]  T. Lim,et al.  Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy , 2020, Cancer communications.

[75]  Alexander H. E. Morrison,et al.  Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity , 2020, Proceedings of the National Academy of Sciences.

[76]  E. Kenigsberg,et al.  A conserved dendritic-cell regulatory program limits antitumour immunity , 2020, Nature.

[77]  D. Toomre,et al.  Platelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes , 2020, Science Advances.

[78]  K. Fitzgerald,et al.  Toll-like Receptors and the Control of Immunity , 2020, Cell.

[79]  Andrea J. Radtke,et al.  The lymph node at a glance – how spatial organization optimizes the immune response , 2020, Journal of Cell Science.

[80]  C. Drake,et al.  Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens , 2019, Nature Biotechnology.

[81]  R. Vonderheide.  CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.

[82]  J. Hubbell,et al.  Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy , 2019, Science Advances.

[83]  R. Weiss,et al.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  R. Vonderheide,et al.  Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. , 2019, Cell systems.

[85]  Jennifer G. Abelin,et al.  Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. , 2019, Immunity.

[86]  Cheryl F. Lichti,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[87]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[88]  N. Hacohen,et al.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance , 2019, Nature Immunology.

[89]  Joseph C. Wu,et al.  Induced Pluripotent Stem Cell-Based Cancer Vaccines , 2019, Front. Immunol..

[90]  C. Swanton,et al.  Resolving genetic heterogeneity in cancer , 2019, Nature Reviews Genetics.

[91]  S. Stevanović,et al.  Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. , 2019, JCI insight.

[92]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[93]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[94]  K. Radford,et al.  The role of dendritic cells in cancer. , 2019, International review of cell and molecular biology.

[95]  H. Sultan,et al.  The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice , 2019, Cancer Immunology, Immunotherapy.

[96]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[97]  J. Sampson,et al.  CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response , 2018, Oncoimmunology.

[98]  M. Kasahara,et al.  The immunoproteasome and thymoproteasome: functions, evolution and human disease , 2018, Nature Immunology.

[99]  J. Wargo,et al.  Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers , 2018, Clinical Cancer Research.

[100]  G. A. van der Marel,et al.  Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System , 2018, The Journal of Immunology.

[101]  Ludmila V. Danilova,et al.  The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity , 2018, Cancer Immunology Research.

[102]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[103]  A. Middelberg,et al.  Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy , 2018, The Journal of clinical investigation.

[104]  Brian J. Stevenson,et al.  Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer , 2018, Science Translational Medicine.

[105]  K. D. de Visser,et al.  Cancer‐Cell‐Intrinsic Mechanisms Shaping the Tumor Immune Landscape , 2018, Immunity.

[106]  D. Farber,et al.  Human T Cell Development, Localization, and Function throughout Life. , 2018, Immunity.

[107]  O. Finn.  The dawn of vaccines for cancer prevention , 2017, Nature Reviews Immunology.

[108]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[109]  T. D. de Gruijl,et al.  Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence , 2017, Cancer Immunology Research.

[110]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[111]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[112]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[113]  P. Cresswell,et al.  The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation. , 2017, Current opinion in immunology.

[114]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[115]  C. Zahnow,et al.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[116]  M. Bhide,et al.  An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction , 2016, Journal of immunology research.

[117]  D. Neuberg,et al.  Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions , 2016, Science Translational Medicine.

[118]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[119]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[120]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[121]  A. Banerjee,et al.  Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response , 2016, Journal of immunology research.

[122]  A. Bardelli,et al.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.

[123]  H. Kohrt,et al.  In situ vaccination for the treatment of cancer. , 2016, Immunotherapy.

[124]  T. Mariani,et al.  CD4+ T Cell Tolerance to Tissue-Restricted Self Antigens Is Mediated by Antigen-Specific Regulatory T Cells Rather Than Deletion. , 2015, Immunity.

[125]  P. Roche,et al.  The ins and outs of MHC class II-mediated antigen processing and presentation , 2015, Nature Reviews Immunology.

[126]  Even Fossum,et al.  Vaccine molecules targeting Xcr1 on cross‐presenting DCs induce protective CD8+ T‐cell responses against influenza virus , 2015, European journal of immunology.

[127]  P. Andersen,et al.  Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. , 2014, Vaccine.

[128]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[129]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[130]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[131]  Søren Buus,et al.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.

[132]  D. Weiner,et al.  Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination , 2011, Gene Therapy.

[133]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[134]  S. Gringhuis,et al.  Signalling through C-type lectin receptors: shaping immune responses , 2009, Nature Reviews Immunology.

[135]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[136]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[137]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[138]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[139]  R. Offringa,et al.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.